Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Bironzo

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Disease|June 29, 2018
A review of guidelines for lung cancerPaolo Bironzo, Massimo Di Maio
Clinical Lung Cancer|August 26, 2018
Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'Paolo Bironzo, Giorgio Vittorio Scagliotti
ESMO Open|June 20, 2020
New emerging targets in cancer immunotherapy: the role of VISTAMarco Tagliamento, Paolo Bironzo, Silvia Novello
Translational Lung Cancer Research|March 10, 2016
Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancerMassimo Di Maio, Paolo Bironzo, Giorgio Vittorio Scagliotti
Expert Review of Anticancer Therapy|September 4, 2014
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancerSimona Carnio, Silvia Novello, Paolo Bironzo, et al.
Healthcare (Basel, Switzerland)|January 8, 2023
Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature ReviewMassimiliano Cani, Paolo Bironzo, Ferdinando Garetto, et al.
Translational Lung Cancer Research|January 25, 2021
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature reviewGianmarco Leone, Francesco Passiglia, Paolo Bironzo, et al.
Translational Lung Cancer Research|January 25, 2021
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle wonFabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, et al.
Future Oncology (London, England)|April 28, 2018
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?Marco Tampellini, Paolo Bironzo, Massimo Di Maio, et al.
Cancer Treatment Reviews|June 26, 2021
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challengesKaushal Parikh, Lizza E L Hendriks, Paolo Bironzo, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Disease|June 29, 2018
A review of guidelines for lung cancerPaolo Bironzo, Massimo Di Maio
Clinical Lung Cancer|August 26, 2018
Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'Paolo Bironzo, Giorgio Vittorio Scagliotti
ESMO Open|June 20, 2020
New emerging targets in cancer immunotherapy: the role of VISTAMarco Tagliamento, Paolo Bironzo, Silvia Novello
Translational Lung Cancer Research|March 10, 2016
Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancerMassimo Di Maio, Paolo Bironzo, Giorgio Vittorio Scagliotti
Expert Review of Anticancer Therapy|September 4, 2014
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancerSimona Carnio, Silvia Novello, Paolo Bironzo, et al.
Healthcare (Basel, Switzerland)|January 8, 2023
Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature ReviewMassimiliano Cani, Paolo Bironzo, Ferdinando Garetto, et al.
Translational Lung Cancer Research|January 25, 2021
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature reviewGianmarco Leone, Francesco Passiglia, Paolo Bironzo, et al.
Translational Lung Cancer Research|January 25, 2021
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle wonFabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, et al.
Future Oncology (London, England)|April 28, 2018
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?Marco Tampellini, Paolo Bironzo, Massimo Di Maio, et al.
Cancer Treatment Reviews|June 26, 2021
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challengesKaushal Parikh, Lizza E L Hendriks, Paolo Bironzo, et al.
Pageof 11